Abstract:LSD1 and HDAC are physical and functional related to each other in various human cancers and simultaneous pharmacological inhibition of LSD1 and HDAC exerts synergistic anti-cancer effects. In this work, a series of novel LSD1/HDAC bifunctional inhibitors with a styrylpyridine skeleton were designed and synthesized based on our previously reported LSD1 inhibitors. The representative compounds 5d and 5m showed potent activity against LSD1 and HDAC at both molecular and cellular level and displayed high selectivity against MAO-A/B. Moreover, compounds 5d and 5m demonstrated potent antiproliferative activities against MGC-803 and HCT-116 cancer cell lines. Notably, compound 5m showed superior in vitro anticancer potency against a panel of gastric cancer cell lines than ORY-1001 and SP-2509 with IC<sub>50</sub> values ranging from 0.23 to 1.56 μM. Compounds 5d and 5m significantly modulated the expression of Bcl-2, Bax, Vimentin, ZO-1 and E-cadherin, induced apoptosis, reduced colony formation and suppressed migration in MGC-803 cancer cells. In addition, preliminary absorption, distribution, metabolism, excretion (ADME) studies revealed that compounds 5d and 5m showed acceptable metabolic stability in human liver microsomes with minimal inhibition of cytochrome P450s (CYPs). Those results indicated that compound 5m could be a promising lead compound for further development as a therapeutic agent in gastric cancers via LSD1 and HDAC dual inhibition.

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Discovery of Novel Pazopanib-based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.

Design, Synthesis and Biological Evaluation of N-Phenylquinazolin-4-Amine Hybrids As Dual Inhibitors of Vegfr-2 and Hdac

Design, Synthesis And Biological Evaluation Of Novel Osimertinib-Based Hdac And Egfr Dual Inhibitors

Design, Synthesis, and Biological Evaluation of Novel HDAC/CD13 Dual Inhibitors for the Treatment of Cancer.

Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives As Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.

Design, Synthesis and Anticancer Evaluation of Acridine Hydroxamic Acid Derivatives As Dual Topo and HDAC Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Benzoylimidazole Derivatives As Raf and Histone Deacetylases Dual Inhibitors.

Design, Synthesis and Biological Evaluation of Pazopanib Derivatives As Antitumor Agents

Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.

Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer

Design, Synthesis and Antitumor Activity Study of PARP-1/HDAC Dual Targeting Inhibitors.

Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Targeting Epigenetic Reader and Eraser: Rational Design, Synthesis and in Vitro Evaluation of Dimethylisoxazoles Derivatives As BRD4/HDAC Dual Inhibitors

Design and Optimization of Novel Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-Substituted Aromatic Amides Bearing Potent Activities Against Tumor Growth and Metastasis

Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Design, synthesis and antitumor activity evaluation of novel HDAC inhibitors with tetrahydrobenzothiazole as the skeleton